Literature DB >> 33257347

Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available.

Andrea Messori1, Laura Bartoli2, Daniele Mengato3,4, Marco Chiumente4,5.   

Abstract

Entities:  

Keywords:  evidence-based medicine; genetic therapy; hematology; public health; statistics

Mesh：

Substances：

Year:  2020        PMID： 33257347      PMCID： PMC9047924          DOI： 10.1136/ejhpharm-2020-002609

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN： 2047-9956


× No keyword cloud information.
  3 in total

1.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors:  Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 Inhibitors.

Authors:  Andrea Messori; Laura Bartoli; Marco Chiumente; Daniele Mengato; Sabrina Trippoli
Journal:  Am J Cardiovasc Drugs       Date:  2020-10-08       Impact factor: 3.571

3.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.